Repurposing Fenofibrate in Modulating mTOR/NLRP3 Inflammasome in Patients With Ulcerative Colitis
Status:
Recruiting
Trial end date:
2024-06-20
Target enrollment:
Participant gender:
Summary
Fibrates, specific pharmacological agonists of PPARα, have been widely used to treat
hypercholesterolemia and hypertriglyceridemia. Apart from their metabolic action,
anti-inflammatory properties of fibrates have been described, including inhibition of
NF-kappa B signaling and pro-inflammatory cytokine production. 4 Fenofibrate, an important
peroxisome proliferator-activated receptor-a (PPAR- α) agonist, is widely used in clinical as
a triglyceride (TG)-lowering agent
Phase:
Phase 2
Details
Lead Sponsor:
Tanta University
Collaborators:
Eman Ibrahim Elberri, Faculty of Pharmacy, Tanta University Fedaa Abd El-monem Kamal El-deen Kotkata Faculty of Pharmacy, Tanta University Manal Ali Mahrous Hamouda Faculty of Pharmacy, Menufia University